One manager, Steve Cohen's Point72, has a waitlist of $9 billion to get into its funds.

Improving economic conditions and a more favorable regulatory environment give Goldman Sachs catalysts to benefit from in the ...

Goldman Sachs analyst Matt Greene maintained a Buy rating on Glencore (GLEN – Research Report) today and set a price target of £5.00. The ...

Barclays downgraded shares of Moderna (NASDAQ:MRNA – Free Report) from an overweight rating to an equal weight rating in a report published on Tuesday, Ratings reports. The firm currently has $45.00 ...

China is starting to see a rebound in M&As as government stimulus measures start to bear fruit and pressure from Donald Trump ...

EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...

In a report released on February 14, Luca Issi from RBC Capital maintained a Hold rating on Moderna (MRNA – Research Report), with a price ...

CSL and Cochlear are two of Australia’s blue-chip healthcare stocks, stalwarts of many investors portfolios, whereas Pro ...

New orders also cascaded 16.4 points lower, though were still positive at 17.8. Barclays downgraded Moderna shares to equal ...

Looking ahead to 2025, Moderna expects revenue of $1.5 to $2.5bn. Credit: Tada Images/Shutterstock. Moderna has reported revenue of $1bn for the fourth quarter (Q4) of 2024 – a sharp decline from the ...

“S&P 500 annual return dispersion in 2024 rose to 70 percentage points, the highest level outside of recessions since 2007,” David Kostin, strategist at Goldman Sachs ... 20.5 Moderna Inc ...